Manufacturing, latest filing in June 2026

Applied Aerospace & Defense, Inc. IPO

Applied Aerospace & Defense, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-05-08. It has amended it 1 time. It filed its final prospectus on 2026-06-04, at a public offering price of $20.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have been approved to list our common stock on the New York Stock Exchange under the symbol “AADX.”From the 424B4 filed 2026-06-04

This is an initial public offering of Applied Aerospace & Defense, Inc. We are offering 32,500,000 shares of our common stock, par value $0.01 per share.From the 424B4 filed 2026-06-04

The initial public offering price per share is $20.00.From the 424B4 filed 2026-06-04

For the fiscal year ended December 31, 2025, we generated $498.8 million in revenue, representing 24.8% year over year growth from revenue of $399.8 million in the fiscal year ended December 31, 2024.From the S-1/A filed 2026-05-26

Additionally, for the fiscal year ended December 31, 2025, we had net loss and Adjusted EBITDA of $17.0 million and $117.9 million, respectively, compared to a net loss and Adjusted EBITDA of $34.8 million and $84.0 million, respectively, in the fiscal year ended December 31, 2024.From the S-1/A filed 2026-05-26

Swipe the table sideways to see every column.

Boundless Group IPO

Boundless Group filed a Form F-1 registration statement for an initial public offering on 2025-10-10. It has amended it 2 times. As of its latest filing, on 2026-06-04, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our Class A ordinary shares on the Nasdaq Capital Market, or Nasdaq, under the symbol “BLTG.” We cannot guarantee that we will be successful in listing our Class A ordinary shares on the Nasdaq; however, we will not complete this offering unless we are so listed.From the F-1/A filed 2026-06-04

We are offering 6,650,000 Class A ordinary shares, par value $0.0001 per share, on a firm commitment basis.From the F-1/A filed 2026-06-04

We intend to use the net proceeds of this offering for research and development (“R&D”), sales, marketing and brands promotion, working capital and other general corporate purposes.From the F-1/A filed 2026-06-04

For the six months ended December 31, 2025 and 2024, we had revenues of approximately $11.90 million and $15.09 million, respectively.From the F-1/A filed 2026-06-04

For the six months ended December 31, 2025 and 2024, our net loss was approximately $0.95 million and $1.02 million, respectively.From the F-1/A filed 2026-06-04

Swipe the table sideways to see every column.

Camerry New Material Tech Ltd. IPO

Camerry New Material Tech Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-06-17. It asked for the registration statement to be withdrawn on 2026-06-16. Each fact below is quoted from the filing named with it.

We intend to list the Class A Ordinary Shares on the Nasdaq Capital Market under the symbol “CNMT”.From the F-1 filed 2025-06-17

We plan to use the net proceeds we receive from this offering for the addition and upgrade of our production equipment, R&D, and working capital.From the F-1 filed 2025-06-17

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Camerry New Material Tech Limited (the “Company”) hereby respectfully requests that the United States Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form F-1 (File No. 333-288105), initially filed with the Commission on June 17, 2025, together with all exhibits and amendments thereto (collectively, the “Registration Statement”), effective as of the date hereof or at the earliest practicable date hereafter.From the RW filed 2026-06-16

Swipe the table sideways to see every column.

Chromarie International Ltd IPO

Chromarie International Ltd filed a Form F-1 registration statement for an initial public offering on 2026-06-03. As of its latest filing, on 2026-06-03, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We are offering 350,000 Class A Ordinary Shares of Chromarie Cayman, at a fixed price of $3.00 per share.From the F-1 filed 2026-06-03

We intend to use the net proceeds from this Offering as follows: approximately 20% for research and development; approximately 15% for expansion of sales and overseas business; approximately 50% for renewal and expansion of production capacity equipment; and the balance to fund for working capital and other general corporate purposes.From the F-1 filed 2026-06-03

Our net income for the fiscal year ended March 31, 2025 was approximately $1.23 million, representing an increase of approximately $0.58 million, or approximately 88.29%, from net income of approximately $0.65 million for the fiscal year ended March 31, 2024.From the F-1 filed 2026-06-03

Swipe the table sideways to see every column.

ERock, Inc. IPO

ERock, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-05-15. It has amended it 3 times. It filed its final prospectus on 2026-06-10, at a public offering price of $21.50 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have been approved to list our Class A common stock on the New York Stock Exchange (“NYSE”) under the symbol “EROC.”From the 424B4 filed 2026-06-10

We are offering 27,906,977 shares of our Class A common stock.From the 424B4 filed 2026-06-10

The initial public offering price is $21.50 per share.From the 424B4 filed 2026-06-10

Our revenue was $31.7 million for the quarter ended March 31, 2026, representing 31.6% year-over-year growth, and $183.1 million for the year ended December 31, 2025, representing 42.5% year-over-year growth.From the S-1/A filed 2026-06-05

Swipe the table sideways to see every column.

Innio N.V. IPO

Innio N.V. filed a Form S-1 registration statement for an initial public offering on 2026-05-11. It has amended it 2 times. It filed its final prospectus on 2026-06-04, at a public offering price of $27.00 per share. Each fact below is quoted from the filing named with it.

We have been approved to list our common shares on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “INIO.”From the 424B4 filed 2026-06-04

The initial public offering price is $27.00 per common share.From the 424B4 filed 2026-06-04

We intend to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses and capital expenditures.From the S-1 filed 2026-05-11

For the three months ended March 31, 2026, we had an Equipment Order Intake (as defined in “ Summary Historical Consolidated Financial and Other Data—Key Operating Metrics and Non-GAAP Financial Measures ”) of $1,617.5 million (resulting in a 147.7% period-over-period increase, from $652.8 million for the three months ended March 31, 2025), $668.6 million in revenue (resulting in a 35.3% period-over-period increase from $494.0 million for the three months ended March 31, 2025), net loss of $9.0 million (reflecting a 125.7% period-over-period change from a net income of $35.0 million for the three months ended March 31, 2025) and an Adjusted EBITDA of $122.5 million (reflecting a 7.5%…From the S-1/A filed 2026-05-26

Swipe the table sideways to see every column.

Kardigan, Inc. IPO

Kardigan, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-05-26. It has amended it 1 time. It filed its final prospectus on 2026-06-18, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on the Nasdaq Global Market (“Nasdaq”) under the symbol “KARD.”From the 424B4 filed 2026-06-18

This is an initial public offering of shares of common stock of Kardigan, Inc. We are offering 25,000,000 shares of our common stock.From the 424B4 filed 2026-06-18

The initial public offering price per share is $16.00.From the 424B4 filed 2026-06-18

We currently intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents and short-term investments to fund the clinical development of Danicamtiv, Ataciguat and Tonlamarsen, to fund other research and development activities, and the remainder for working capital and other general corporate purposes.From the 424B4 filed 2026-06-18

Our net losses totaled $56.1 million and $18.0 million for the three months ended March 31,From the S-1/A filed 2026-06-11

Swipe the table sideways to see every column.

Kilcoy Global Foods, Ltd. IPO

Kilcoy Global Foods, Ltd. filed a Form F-1 registration statement for an initial public offering on 2025-06-16. It has amended it 1 time. It asked for the registration statement to be withdrawn on 2026-06-24. Each fact below is quoted from the filing named with it.

We have submitted an application for the listing of the ADSs on Nasdaq under the symbol “KGF.”From the F-1/A filed 2025-06-27

We intend to use the net proceeds from this offering for potential strategic investments and acquisitions, expanding our productionFrom the F-1/A filed 2025-06-27

For the year ended December 31, 2024, we recorded a total revenue of US$2,195.0 million, increasing by 17.3% from US$1,870.7 million for the year ended December 31, 2023.From the F-1/A filed 2025-06-27

Net income increase from US$34.7 million in 2023, to US$60.4 million in 2024, representing an increase of 74.1%; andFrom the F-1/A filed 2025-06-27

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the Commission consent to the withdrawal of the Registration Statement effective as of the date hereof.From the RW filed 2026-06-24

Swipe the table sideways to see every column.

Lagarosse Holdings Ltd IPO

Lagarosse Holdings Ltd filed a Form F-1 registration statement for an initial public offering on 2026-06-30. As of its latest filing, on 2026-06-30, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We plan to apply to list our Class A Ordinary Shares on the NYSE American or the Nasdaq Capital Market We have reserved the symbol “LAGH” with the Nasdaq Capital Market.From the F-1 filed 2026-06-30

We intend to use the net proceeds of this Offering for (i) investment in Château Lagarosse, including funding renovation of the heritage château buildings, vineyard development, and upgrades to winery facilities and equipment;From the F-1 filed 2026-06-30

For the six months interim financial period ended September 30, 2025, we generated revenue of €1,200,690 (US$1,404,807), representing an increase of 20,538% from the corresponding period ended September 30, 2024, during which revenue amounted to approximately €5,818.From the F-1 filed 2026-06-30

We achieved net loss of €170,548 and income of €610,114 (US$713,833), respectively for the six months interim financial period ended September 30, 2024 and 2025.From the F-1 filed 2026-06-30

Swipe the table sideways to see every column.

MED EIBY Holding Co., Ltd IPO

MED EIBY Holding Co., Ltd has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-11-01. Amendments on record here: 3. It asked for the registration statement to be withdrawn on 2026-06-16. Each fact below is quoted from the filing named with it.

W e expect to list the Ordinary Shares on the Nasdaq Capital Market (“Nasdaq”) under the symbol “BSME.” At this time, Nasdaq has not yet approved our application to list our Ordinary Shares.From the F-1/A filed 2025-01-17

Pursuant to Rule 477 under the Securities Act of 1933 (the “Act”), MED EIBY HOLDING CO., LIMITED (the “Company”) respectfully requests the immediate withdrawal of its Registration Statement on Form F-1 (File No. 333-270018) initially filed with the U.S. Securities and Exchange Commission (the “Commission”) on February 24, 2023, together with all exhibits, amendments and post-effective amendments thereto (the “Registration Statement”), with such application to be approved effective as of the date hereof or at the earliest practical date thereafter.From the RW filed 2026-06-16

Swipe the table sideways to see every column.

MetaOptics Ltd IPO

MetaOptics Ltd filed a Form F-1 registration statement for an initial public offering on 2026-05-04. It has amended it 2 times. As of its latest filing, on 2026-06-10, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have submitted an application to list the ADSs on the Nasdaq Capital Market under the symbol “MOT.” We have obtained approval from Catalist of the SGX -ST , acting as agent on behalf of the Monetary Authority of Singapore, to deal in, and for the listing and quotation of, all the ordinary shares represented by the ADSs we are offering.From the F-1/A filed 2026-06-10

We intend to use the net proceeds from this offering primarily to support our expansion plans in the United States.From the F-1/A filed 2026-06-10

Global revenue grew from about US$2.3 million in 2020 to US$64.5 million in 2025, representing a CAGR of 94.5%, with consumer electronics leading and automotive and security rising; penetration in consumer electronics was about 1.2% in 2025, indicating significant runway and a rapidly expanding total addressable market, according to the Independent Market Report.From the F-1/A filed 2026-06-10

We reported net losses of S$5,445,573 and S$1,950,882 for the years ended December 31, 2025 and December 31, 2024, respectively.From the F-1/A filed 2026-06-10

Swipe the table sideways to see every column.

Parabilis Medicines, Inc. IPO

Parabilis Medicines, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-05-19. It has amended it 3 times. It filed its final prospectus on 2026-06-10, at a public offering price of $20.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “PBLS”.From the 424B4 filed 2026-06-10

This is an initial public offering of shares of common stock of Parabilis Medicines, Inc. We are offering 33,500,000 shares of our common stock.From the 424B4 filed 2026-06-10

The initial public offering price per share is $20.00.From the 424B4 filed 2026-06-10

We currently intend to use the net proceeds we receive from this offering, to continue the ongoing clinical development of zolucatetide in desmoid tumors, to continue the ongoing clinical development of zolucatetide across several additional indications, to advance our pipeline of additional programs, and the remainder for continued evolution of the Helicon platform and for general corporate purposes, including additional development efforts, working capital and operating expenses.From the 424B4 filed 2026-06-10

We have incurred net losses in each year since our inception in 2015, including net losses of $117.9 million and $145.9 million for the years ended December 31, 2024 and 2025, respectively and $38.3 million and $45.3 million for the three months ended March 31, 2025 and 2026, respectively.From the S-1/A filed 2026-06-09

Swipe the table sideways to see every column.

ROKIT America, Inc. IPO

ROKIT America, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-04-15. It has amended it 2 times. As of its latest filing, on 2026-06-04, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our Common Stock on the Nasdaq under the symbol “RKAM” and this offering is contingent upon obtaining approval of such listing.From the S-1/A filed 2026-06-04

We anticipate that the initial public offering price will be between $8.50 and $10.50 per share, and the number of shares of common stock offered hereby is based upon an assumed offering price of $9.50 per share, which is the midpoint of such estimated price range.From the S-1/A filed 2026-06-04

Consistent with this revenue growth, the Company also reported net income of approximately $432,694 and $243,713 for the three months ended March 31, 2026 and 2025, respectively.From the S-1/A filed 2026-06-04

Swipe the table sideways to see every column.

SAMFINE CREATION HOLDINGS GROUP Ltd IPO

SAMFINE CREATION HOLDINGS GROUP Ltd filed a Form F-1 registration statement for an initial public offering on 2026-06-11. It has amended it 3 times. It filed its final prospectus on 2024-10-15. Each fact below is quoted from the filing named with it.

Our Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “SFHG.” The last reported sale price of our Class A Ordinary Shares on the Nasdaq Capital Market on June 29, 2026, was $2.19 per share.From the F-1/A filed 2026-06-30

We are offering 2,000,000 Ordinary Shares of Samfine Creation Holdings Group Limited (“SFHG”), representing 10.00% of the Ordinary Shares following the completion of this offering, assuming the underwriters do not exercise their over -allotment option.From the 424B4 filed 2024-10-15

The offering price of our Ordinary Shares in this offering is expected to be between $4.00 and $5.00 per Ordinary Share.From the F-1/A filed 2024-08-07

We intend to use the net proceeds as follows:From the F-1/A filed 2026-06-30

Our revenue increased by 30.9% to HK$153,493,065 for the year ended December 31, 2024 from HK$117,265,596 for the year ended December 31, 2023.From the F-1/A filed 2026-06-30

Swipe the table sideways to see every column.